Leading project coordination (WP5). Discovering novel common genetic variants and gaining insights into their putative roles in ALD-HCC development (WP1)

To coordinate WP2, which evaluates gene-environment interactions for the risk of ALD-HCC development at molecular level, together with TUD and performing spatial metabolomics/lipidomics analysis.

The European Liver Patients’ Association (ELPA) plays a vital role in the GENIAL project by representing patient voices and addressing their unmet needs. As a patients’ association, ELPA is dedicated to communication and dissemination, ensuring that the project’s goals and findings are effectively conveyed to patient communities, civil society, and policymakers.

To achieve these objectives, ELPA will: organize laymen events communicating the project’s impact in accessible language, making complex information understandable to a general audience, formulate recommendations aimed at addressing healthcare inequalities, ensuring that the project’s findings lead to actionable changes, create informative videos where principal investigators (PIs) will explain the project in easy-to-understand terms through a series of videos, making scientific information accessible to a wider audience, represent the project at key European and international congresses, broadening the project’s reach and impact and implement an outreach strategy which will maximize the project’s impact by leveraging ELPA’s extensive online platforms for information dissemination. This strategy will utilize ELPA’s network for wider engagement and support, providing a diverse platform to amplify the project’s impact across Europe through a network of 32 organizations from 25 countries. ELPA is also the leader of the “Understanding Inequalities in Access to Cancer Care in EU” Cluster, being part of the an umbrella EU Cancer Mission Cluster.

Through these efforts, ELPA will ensure that the GENIAL project reaches its target audiences and achieves its goals of addressing healthcare inequalities and improving liver health outcomes across Europe.

To coordinate the identification of genetic variants predisposing to ALD HCC. To lead identification of rare genetic variants.

To review histological slides stratified by genotypes.

To evaluate the impact of environmental risk factors, in particular dietary intakes and physical activity, on the occurrence of HCC in ALD and NAFLD cirrhotic patients.

To lead functional validation of hepatic metabolism and gene-environment interactions in preclinical models.

To evaluate ALD-HCC risk variants in the general population and in cohorts.

Partner

To define cellular heterogeneity and genomic programs by snRNA-seq.

With experience in diagnostic Ai solutions in clinical use, Stratipath will implement the prognostic models integrating all data with industrial-grade quality control mechanisms.

To evaluate the impact of environmental risk factors, in particular dietary intakes and physical activity, on the occurrence of HCC in ALD and NAFLD cirrhotic patients.

To assist the coordinator at Université Libre de Bruxelles in the overall coordination (administrative, financial and strategic support) as well as in the communication, dissemination and exploitation activities of the project.

To disseminate and communicate, to promote the project, to share the results and to inform the liver community about the GENIAL project, its activities and its findings.

Associated partner